Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Xie, Cheng Long ^a   Wang, Wen Wen ^b   Zhang, Su Fang ^a   Yuan, Ming Lu ^c   Che, Jun Yi ^c   Gan, Jing ^a   Song, Lu ^a   Yuan, Wei En ^c   Liu, Zhen Guo ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; BENSERAZIDE; BENSERAZIDE, LEVODOPA DRUG COMBINATION; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOPAMINE RECEPTOR STIMULATING AGENT; DOWN-REGULATOR OF TRANSCRIPTION 1; DRUG COMBINATION; LACTIC ACID; LEVODOPA; MAPT PROTEIN, RAT; MESSENGER RNA; MICROSPHERE; OXIDOPAMINE; PHOSPHOPROTEIN; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; TAU PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL; CORPUS STRIATUM; CYTOLOGY; DRUG COMBINATION; DRUG EFFECTS; DYSKINESIAS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; NERVE CELL; PARKINSON DISEASE; PATHOLOGY; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ADRENERGIC AGENTS; ANIMALS; BENSERAZIDE; BLOTTING, WESTERN; CORPUS STRIATUM; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOPAMINE AGENTS; DRUG COMBINATIONS; DYSKINESIAS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; LACTIC ACID; LEVODOPA; MICROSPHERES; NEURONS; OXIDOPAMINE; PARKINSON DISEASE; PHOSPHOPROTEINS; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TAU PROTEINS; TRANSCRIPTION FACTORS;

EID: 84947907975     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07506     Document Type: Article

References (30)

1. Akushevich, I., Kravchenko, J., Ukraintseva, S., Arbeev, K. & Yashin, A. I. Age patterns of incidence of geriatric disease in the U.S. elderly population: Medicarebased analysis. J Am Geriatr Soc 60, 323-327 (2012).
2. Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H. & Brotchie, J. M. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev 65, 171-222 (2013).
3. Bhidayasiri, R. & Truong, D. D. Motor complications in Parkinson disease: clinical manifestations and management. J Neurol Sci 266, 204-215 (2008).
4. Dodel, R. C., Berger, K. & Oertel, W. H. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 19, 1013-1038 (2001).
5. Iravani, M. M. & Jenner, P. Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm 118, 1661-1690 (2011).
6. Jenner, P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9, 665-677 (2008).
7. Olanow, C. W., Obeso, J. A. & Stocchi, F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 5, 677-687 (2006).
8. Bezard, E. Experimental reappraisal of continuous dopaminergic stimulation against L-dopa-induced dyskinesia. Mov Disord 28, 1021-1022 (2013).
9. Olanow, C. W. et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13, 141-149 (2014).
10. Berthet, A. & Bezard, E. Dopamine receptors and L-dopa-induced dyskinesia. Parkinsonism Relat Disord 15, S8-12 (2009).
11. Aubert, I. et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57, 17-26 (2005).
12. Calabresi, P., Di Filippo, M., Ghiglieri, V., Tambasco, N. & Picconi, B. Levodopainduced dyskinesias in patients with Parkinson's disease: filling the bench-tobedside gap. Lancet Neurol 9, 1106-1117 (2010).
13. Feyder, M., Bonito-Oliva, A. & Fisone, G. L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission. Front Behav Neurosci 5, 71 (2011).
14. Lebel, M., Chagniel, L., Bureau, G. & Cyr, M. Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat. Neurobiol Dis 38, 59-67 (2010).
15. Yang, X. et al. Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDAlesioned rats. Drug Des Devel Ther 6, 341-347 (2012).
16. Yang, X. et al. Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats. Int JNanomedicine 7, 2077-2086 (2012).
17. Wright, B. A. & Waters, C. H. Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease. Expert Rev Neurother 13, 719-729 (2013).
18. Gershanik, O. & Jenner, P. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease. Eur J Neurol 19, 1502-1508 (2012).
19. Calabresi, P., Di Filippo, M., Ghiglieri, V. & Picconi, B. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord 23, S570-579 (2008).
20. Fiorentini, C., Savoia, P., Savoldi, D., Barbon, A. & Missale, C. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease. Neurobiol Dis 54, 339-348 (2013).
21. Picconi, B. et al. Loss of bidirectional striatal synaptic plasticity in L-DOPAinduced dyskinesia. Nat Neurosci 6, 501-506 (2003).
22. Berthet, A. et al. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. J Neurosci 29, 4829-4835 (2009).
23. Santini, E., Valjent, E. & Fisone, G. Parkinson's disease: levodopa-induced dyskinesia and signal transduction. FEBS J 275, 1392-1399 (2008).
24. Martinez, A., Macheda, T., Morgese, M. G., Trabace, L. & Giuffrida, A. The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats. Neurosci Res 72, 236-242 (2012).
25. Arendt, T. et al. Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals. J Neurosci 23, 6972-6981 (2003).
26. Mazanetz, M. P. & Fischer, P. M. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 6, 464-479 (2007).
27. Lebel, M., Patenaude, C., Allyson, J., Massicotte, G. & Cyr, M. Dopamine D1 receptor activation induces tau phosphorylation via cdk5 and GSK3 signaling pathways. Neuropharmacology 57, 392-402 (2009).
28. Lindenbach, D. et al. Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat. J Pharmacol Exp Ther 337, 755-765 (2011).
29. Cenci, M. A., Lee, C. S. & Björklund, A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10, 2694-2706 (1998).
30. Schallert, T., Fleming, S. M., Leasure, J. L., Tillerson, J. L. & Bland, S. T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39, 777-787 (2000).